ATE210656T1 - Heterocyclische ether-derivate zur verstärkung der cognitiven funktionen - Google Patents

Heterocyclische ether-derivate zur verstärkung der cognitiven funktionen

Info

Publication number
ATE210656T1
ATE210656T1 AT93923826T AT93923826T ATE210656T1 AT E210656 T1 ATE210656 T1 AT E210656T1 AT 93923826 T AT93923826 T AT 93923826T AT 93923826 T AT93923826 T AT 93923826T AT E210656 T1 ATE210656 T1 AT E210656T1
Authority
AT
Austria
Prior art keywords
heterocyclic ether
ether derivatives
cognitive functions
enhance cognitive
cholinergic
Prior art date
Application number
AT93923826T
Other languages
English (en)
Inventor
Melwyn A Abreo
David E Gunn
Nan-Horng Lin
Richard L Elliott
David S Garvey
Suzanne A Lebold
James T Wasicak
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE210656T1 publication Critical patent/ATE210656T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT93923826T 1992-10-09 1993-10-08 Heterocyclische ether-derivate zur verstärkung der cognitiven funktionen ATE210656T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95900592A 1992-10-09 1992-10-09
PCT/US1993/009662 WO1994008992A1 (en) 1992-10-09 1993-10-08 Heterocyclic ether compounds that enhance cognitive function

Publications (1)

Publication Number Publication Date
ATE210656T1 true ATE210656T1 (de) 2001-12-15

Family

ID=25501548

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93923826T ATE210656T1 (de) 1992-10-09 1993-10-08 Heterocyclische ether-derivate zur verstärkung der cognitiven funktionen

Country Status (12)

Country Link
EP (1) EP0663912B1 (de)
JP (1) JP3098035B2 (de)
KR (1) KR100311546B1 (de)
AT (1) ATE210656T1 (de)
AU (1) AU687017B2 (de)
CA (1) CA2136075C (de)
DE (1) DE69331329T2 (de)
DK (1) DK0663912T3 (de)
ES (1) ES2169727T3 (de)
IL (1) IL107184A (de)
PT (1) PT663912E (de)
WO (1) WO1994008992A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948793A (en) * 1992-10-09 1999-09-07 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5998404A (en) * 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
IL118279A (en) * 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
WO1997017955A1 (en) * 1995-11-13 1997-05-22 Eli Lilly And Company Method for treating anxiety
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
US6979695B2 (en) 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6437138B1 (en) 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5629325A (en) * 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
ES2189003T3 (es) * 1996-12-10 2003-07-01 Abbott Lab Enantiomeros 3-piridilo y su utilizacion como analgesicos.
US6133253A (en) * 1996-12-10 2000-10-17 Abbott Laboratories 3-Pyridyl enantiomers and their use as analgesics
CA2287223A1 (en) * 1997-04-26 1998-11-05 Tomohiro Toyoda 2-azabicyclo compounds
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6525065B1 (en) 1997-06-30 2003-02-25 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6624173B1 (en) 1997-06-30 2003-09-23 Targacept, Inc. Pharmaceutical compositions for treating and/or preventing CNS disorders
EP1034174B1 (de) 1997-11-05 2003-08-13 Neurosearch A/S Azaring-ether-derivate und ihre verwendung als nicotinic-ach-rezeptormodulatoren
EP1047690B1 (de) * 1997-12-19 2004-03-24 Abbott Laboratories Heterozyklische ether- und thioether-verbindungen, verwendbar zur steuerung von chemischer synaptischer transmission
ES2199561T3 (es) * 1998-04-02 2004-02-16 Targacept, Inc. Derivados de azatriciclo(3.3.1.1)decano y composiciones farmaceuticas que los contienen.
KR20010052171A (ko) 1998-04-02 2001-06-25 알. 제이. 레이놀즈 터베코 컴퍼니 의약 조성물 및 그 사용방법
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
US6544976B1 (en) 1999-07-09 2003-04-08 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
CA2381252A1 (en) * 1999-09-14 2001-03-22 Abbott Laboratories 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
US6890935B2 (en) 1999-11-01 2005-05-10 Targacept, Inc. Pharmaceutical compositions and methods for use
US6812314B2 (en) 2001-10-17 2004-11-02 University Of Florida Thermally responsive polymer materials and uses thereof
PL374384A1 (en) 2001-12-14 2005-10-17 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
AU2003245753B2 (en) 2002-07-05 2009-12-24 Targacept, Inc. N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
WO2004009775A2 (en) 2002-07-19 2004-01-29 Targacept, Inc. Methods and compositions relating to chimeric nicotinic receptor subunits
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
AU2004282201A1 (en) 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
EP1802258A4 (de) 2004-09-13 2015-09-23 Chrono Therapeutics Inc Biosynchrone transdermale arzneiabgabe
JP2008513482A (ja) 2004-09-20 2008-05-01 ターガセプト，インコーポレイテッド ニコチン性コリン作動性受容体活性を有するアザスピロアルケンおよびアザピロアルカン
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
DE602006017235D1 (de) 2005-08-22 2010-11-11 Targacept Inc Heteroarylsubstituierte diazatricycloalkane, verfahren zu deren herstellung und deren anwendung
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
CN101528698A (zh) 2006-05-09 2009-09-09 阿斯利康公司 (2s)-(4e)-n-甲基-5-[3-(5-异丙氧基吡啶)基]-4-戊烯-2-胺的盐形式
TWI405763B (zh) 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
JP2010511014A (ja) * 2006-11-29 2010-04-08 ビーエーエスエフ ソシエタス・ヨーロピア 害虫を駆除するためのピリジン化合物
US20100028447A1 (en) 2007-01-22 2010-02-04 Targacept, Inc. Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs
TW200845977A (en) 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
GB2448224B (en) 2007-04-02 2010-09-01 Parkinson S Inst Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8114891B2 (en) 2007-10-01 2012-02-14 Comentis, Inc. 4-substituted quinuclidine derivatives, methods of production, pharmaceutical uses thereof
KR20110091501A (ko) * 2008-10-14 2011-08-11 싸이코제닉스 아이엔씨. 니코틴성 아세틸콜린 수용체 리간드 및 이들의 용도
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
EP3279195B1 (de) 2008-12-01 2020-07-01 Oyster Point Pharma, Inc. Synthese und neuartige salzformen von (r)-5-((e)-2-pyrrolidin-3-ylvinyl)pyrimidin
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP2013512922A (ja) 2009-12-07 2013-04-18 ターガセプト，インコーポレイテッド 神経型ニコチン性アセチルコリン受容体リガンドとしての３，６−ジアザビシクロ［３．１．１］ヘプタン
WO2011146009A1 (en) 2010-05-20 2011-11-24 Targacept Inc. New process for the preparation of aryl substituted olefinic amines
PL2576496T3 (pl) 2010-05-27 2017-08-31 Catalyst Biosciences, Inc. Niekompetycyjni antagoniści receptorów nikotynowych
WO2012125518A1 (en) 2011-03-14 2012-09-20 Targacept, Inc. Salt forms of 3 - cyclopropylcarbonyl - 3, 6 - diazabicyclo [3.1.1] heptane
WO2012129262A1 (en) 2011-03-23 2012-09-27 Targacept, Inc. Treatment of attention deficit/hyperactivity disease
TW201311698A (zh) 2011-08-22 2013-03-16 Targacept Inc 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷
US9303017B2 (en) 2011-11-11 2016-04-05 Georgetown University 2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof
TW201617342A (zh) 2014-07-11 2016-05-16 阿法馬根公司 調節α７活性之啶類
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
CN105418477B (zh) * 2015-12-22 2018-12-21 爱斯特（成都）生物制药股份有限公司 降低雷迪帕韦中间体中非对映异构体杂质含量的方法
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
AU2019279884A1 (en) 2018-05-29 2020-12-10 Morningside Venture Investments Limited Drug delivery methods and systems

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA848275B (en) * 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
CA1307790C (en) * 1987-08-04 1992-09-22 Ian Anthony Cliffe Ethers
YU84791A (sh) * 1990-05-19 1994-06-10 Boehringer Ingelheim Kg. Biciklicni 1-aza-cikloalkalni

Also Published As

Publication number Publication date
WO1994008992A1 (en) 1994-04-28
EP0663912A4 (de) 1995-02-17
CA2136075A1 (en) 1994-04-28
IL107184A0 (en) 1994-01-25
EP0663912B1 (de) 2001-12-12
DE69331329D1 (de) 2002-01-24
EP0663912A1 (de) 1995-07-26
AU687017B2 (en) 1998-02-19
KR950701920A (ko) 1995-05-17
PT663912E (pt) 2002-06-28
CA2136075C (en) 2004-12-14
DK0663912T3 (da) 2002-04-15
AU5355794A (en) 1994-05-09
JPH08502481A (ja) 1996-03-19
JP3098035B2 (ja) 2000-10-10
IL107184A (en) 1997-08-14
KR100311546B1 (ko) 2005-12-06
DE69331329T2 (de) 2002-08-08
ES2169727T3 (es) 2002-07-16

Similar Documents

Publication Publication Date Title
ATE210656T1 (de) Heterocyclische ether-derivate zur verstärkung der cognitiven funktionen
FI931888A (fi) Kramploesande cykliska fruktopyranossulfiter -och sulfater
DE69505470D1 (de) Pyrrolocarbazol
TW429255B (en) Pyrazine compounds having treatment of central nervous system diseases and disorders
ES2195500T3 (es) Dereivados del 2-indanometanol y su utilizacion a titulo de ingredientes perfumantes.
PT1049672E (pt) Derivados de azetidinocarboxamida para o tratamento de disturbios do snc
DK0623131T3 (da) Alkylderivater af trazodon med CNS-aktivitet
SE8901060D0 (sv) New compounds
DK0784973T3 (da) Quinoxalinderivater til behandling af tinnitus
DK52383D0 (da) Fremgangsmade til fremstilling af carbacyklinderivater
PT1049670E (pt) Derivados de azetidinocarboxamida para o tratamento de perturbacoes do snc
ES2004215A6 (es) Procedimiento para preparar quinazolinas tetraciclicas
ES8705363A1 (es) Un procedimiento para preparar derivados de tetrahidronaftaleno
ATE28628T1 (de) Phenylethylaminderivate und ihre zwischenprodukte.
FI933652A (fi) Foerfarande foer framstaellning av 1-osubstituerade 3-aminopyrroler

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification